High-dose rate brachytherapy in prostate cancer patients--a study on nausea and vomiting.
High-dose rate brachytherapy (HDRB) is one of many treatments for prostate cancer. Despite a reported 80% to 90% success rate in terms of cure rates, nausea and vomiting have been noted as a significant problem. At St. Vincent's Private Hospital, an incidence of nausea and vomiting was estimated at 67% of patients undergoing HDRB. This study examines the possible causes and risk factors of post-operative nausea and vomiting with this treatment option.
Keats
Sue
S
Clinical Support Unit, St. Vincent's Private Hospital, Sydney Australia.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009517:New South Wales; D020250:Postoperative Nausea and Vomiting / Q000209:etiology* / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D012189:Retrospective Studies; D012307:Risk Factors